P-21 Peptide

Overview

P-21 is a neuroprotective peptide derived from the colivelin family — a series of synthetic neuropeptides developed by combining humanin (a mitochondria-encoded neuropeptide) with ADNF18 (activity-dependent neurotrophic factor fragment). P-21 represents a simplified, shorter active fragment with potent anti-Alzheimer's activity in preclinical models.

Important name disambiguation: P-21 (the neuropeptide profiled here) is entirely different from p21/CDKN1A — the cyclin-dependent kinase inhibitor protein involved in cell cycle arrest. These share only a name and have no mechanistic relationship.

Mechanism

STAT3/JAK2 Signaling

P-21's primary signaling mechanism proceeds through:

1. P-21 binds a cell-surface receptor in the CNTF receptor complex family (gp130-related)
2. Activates JAK1/2 tyrosine kinases
3. JAK2 phosphorylates STAT3 at Tyr-705
4. pSTAT3 dimerizes → enters nucleus
5. Activates anti-apoptotic, neurotrophic, and neuroprotective gene programs (Bcl-xL, SOCS3, neurotrophins)

Amyloid-Beta Clearance

A key proposed mechanism for AD relevance:

• Insulin-degrading enzyme (IDE) upregulation: IDE cleaves amyloid-beta monomers and oligomers; STAT3 activation increases IDE expression
• Neprilysin upregulation: The primary amyloid-degrading enzyme in the brain; P-21 increases neprilysin activity in neural tissue
• Reduced BACE1 expression: β-secretase activity (which generates Aβ) is reduced by STAT3-pathway activation

Tau Phosphorylation Inhibition

P-21 reduces activation of GSK-3β, the primary kinase responsible for tau hyperphosphorylation. Less tau phosphorylation → less tau aggregation into neurofibrillary tangles.

mTOR-AMPK Modulation

Emerging evidence suggests P-21 may modulate mTOR signaling toward an AMPK-dominant state — a metabolic shift associated with longevity (similar to rapamycin's mechanism) applied specifically in neuronal contexts.

Cognitive Research Context

In Alzheimer's mouse models (APP/PS1 and 3xTg-AD), P-21 administration:

• Reduced amyloid plaque burden in cortex and hippocampus
• Improved Morris water maze performance (spatial learning and memory)
• Reduced inflammatory microglial activation
• Extended survival in ALS models (extended from humanin research)

The intranasal route is prioritized because it allows direct brain access while avoiding peripheral STAT3 effects that could be concerning with systemic chronic administration.

Comparison to Related Neuropeptides

| Peptide | Origin | Primary Target | Key Mechanism | |---------|--------|---------------|---------------| | P-21 | Synthetic (colivelin derivative) | Alzheimer's, neuroprotection | STAT3/JAK2, amyloid clearance | | Humanin | Mitochondrial genome | Apoptosis, IGF-1 signaling | STAT3, Bax inhibition | | DSIP | Hypothalamic | Sleep, stress | Delta sleep induction | | Pinealon | Pineal peptide bioregulator | Cognitive, circadian | Epigenetic regulation | | Dihexa | Angiotensin IV analogue | BDNF pathway | HGF/c-Met signaling |